Last checked at 22 Nov 2023 09:48
LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News
GSK Share
Chat
GSK Share
Trades8,855
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,733.50
Bid:
1,732.50
Ask:
1,733.00
Change:
5.00 (0.29%)
Spread:
0.50 (0.029%)
Open:
1,733.00
High:
1,739.50
Low:
1,724.50
Prev. Close:
1,728.50
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.GSK bets $300m on tie-up with gene-tester 23andMe
Wed, 25th Jul 2018 11:06
(Sharecast News) - GlaxoSmithKline has invested $300m (£228m) in 23andMe, a Silicon Valley gene-testing company, as the UK drugs giant looks to genetics to improve growth in its pharmaceuticals division. Announcing second-quarter results, GSK said the deal would give it exclusive access to 23andMe's DNA database as a resource for finding new treatments.GSK said the deal was an important part of its new approach to research focused on the biology of the immune system and genetic evidence.The four-year agreement will combine 23andMe's genetic database with GSK's medical experience and commercial heft.23andMe has more than 5m customers, more than 80% of which have agreed to allow their data to be used for research.The Google-backed US company is known for test kits that let users find out about their genetic roots with a sample of saliva. But it also has a research and development division that has come up with early stage therapies.The companies will combine existing projects and form a joint drug discovery team to identify target diseases based on the strength of biological evidence.Hal Barron, who joined GSK as chief scientist in January, said: "Drug targets with genetic validation have a significantly higher chance of ultimately demonstrating benefit for patients and becoming medicines. Partnering with 23andMe...will help to shift our research and development organisation to be 'driven by genetics', and increase the impact GSK can have on patients."Project costs will be split equally with room for both sides to reduce its share for a particular programme. GSK has taken a $300m equity stake in 23andMe.As far as the results are concerned, GSK said group sales in the second quarter rose 4% excluding currency swings to £7.3bn. Pharmaceutical sales were the weakest of GSK's three divisions, rising 1% to £4.2bn compared with 16% from vaccines and 3% from healthcare at constant currency. GSK announced a plan to spend £1.7bn over thee years to save £400m a year in supply chain and administration costsEmma Walmsley, GSK's chief executive, said: "GSK has delivered encouraging results across the company this quarter with CER (constant exchange rate) sales growth in each of our three global businesses. We have announced the start of a new approach to R&D which aims to capitalise on the assets we have in our promising early-stage pipeline and build the next wave of growth for GSK."The company increased its target for adjusted earnings growth to 7-10% if no generic competitor for its Advair product hits the US market in 2018.
More News
21 Nov 2023 11:52
GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024
(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.
Read more14 Nov 2023 17:04
LONDON MARKET CLOSE: FTSE 100 underwhelms as stocks jump after US CPI
(Alliance News) - European equities jumped in the wake of a cooler-than-expected US inflation reading, which took some sting out of a recent hawkish reassessment of the Federal Reserve interest rate outlook.
Read more13 Nov 2023 09:47
GSK hails momelotinib opinion from European Medicines Agency committee
(Alliance News) - GSK PLC on Monday announced that a European Medicines Agency panel has given a positive opinion recommending momelotinib to treat myelofibrosis patients with anaemia.
Read more9 Nov 2023 15:50
UK dividends calendar - next 7 days
| Friday 10 November | |
| Bodycote PLC | dividend payment date |
| Breedon Group PLC | dividend payment date |
| Chesnara PLC | dividend payment date |
| Finsbury Growth & Income Trust PLC | dividend payment date |
| Invesco Bond Income Plus Ltd | dividend payment date |
| JPMorgan Emerging Markets Investment Trust PLC | dividend payment date |
| Kerry Group PLC | dividend payment date |
| Merchants Trust PLC | dividend payment date |
| Mid Wynd International Investment Trust PLC | dividend payment date |
| Mid Wynd International Investment Trust PLC | special dividend payment date |
| Montanaro UK Smaller Cos Investment Trust PLC | dividend payment date |
| Senior PLC | dividend payment date |
| Spectris PLC | dividend payment date |
| Spirax-Sarco Engineering PLC | dividend payment date |
| Travis Perkins PLC | dividend payment date |
| Monday 13 November | |
| no events scheduled | |
| Tuesday 14 November | |
| no events scheduled | |
| Wednesday 15 November | |
| Coats Group PLC | dividend payment date |
| Ferguson PLC | dividend payment date |
| JP Morgan Mid Cap Investment Trust PLC | dividend payment date |
| Strategic Equity Capital PLC | dividend payment date |
| Thursday 16 November | |
| abrdn Property Income Trust Ltd | ex-dividend payment date |
| Asian Energy Impact Trust PLC | ex-dividend payment date |
| Baillie Gifford Japan Trust PLC | ex-dividend payment date |
| BlackRock Greater Europe Investment Trust PLC | ex-dividend payment date |
| Bunzl PLC | ex-dividend payment date |
| Bytes Technology Group PLC | ex-dividend payment date |
| Centrica PLC | dividend payment date |
| Coca-Cola Europacific Partners PLC | ex-dividend payment date |
| DX Group PLC | ex-dividend payment date |
| Empiric Student Property PLC | ex-dividend payment date |
| Fonix Mobile PLC | ex-dividend payment date |
| GCP Asset Backed Income Fund Ltd | ex-dividend payment date |
| GSK PLC | ex-dividend payment date |
| Hargreaves Lansdown PLC | ex-dividend payment date |
| Henderson Opportunities Trust PLC | ex-dividend payment date |
| ICG Enterprise Trust PLC | ex-dividend payment date |
| James Halstead PLC | ex-dividend payment date |
| Lancashire Holdings Ltd | special ex-dividend payment date |
| Majedie Investments PLC | ex-dividend payment date |
| Marks & Spencer Group PLC | ex-dividend payment date |
| Murray Income Trust PLC | ex-dividend payment date |
| New Star Investment Trust PLC | ex-dividend payment date |
| NextEnergy Solar Fund Ltd | ex-dividend payment date |
| Octopus Renewables Infrastructure Trust PLC | ex-dividend payment date |
| Pershing Square Holdings Ltd | ex-dividend payment date |
| Personal Group Holdings PLC | dividend payment date |
| Redrow PLC | dividend payment date |
| Regional REIT Ltd | ex-dividend payment date |
| Schroder Oriental Income Fund Ltd | ex-dividend payment date |
| Scottish American Investment Co PLC | ex-dividend payment date |
| SCS Group PLC | ex-dividend payment date |
| Shell PLC | ex-dividend payment date |
| Supermarket Income REIT PLC | dividend payment date |
| UK Commercial Property REIT Ltd | ex-dividend payment date |
| Unilever PLC | ex-dividend payment date |
| Wincanton PLC | ex-dividend payment date |
| Copyright 2023 Alliance News Ltd. All Rights Reserved. | |
8 Nov 2023 09:30
LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
Read more2 Nov 2023 10:14
LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy'
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:
Read more1 Nov 2023 16:52
LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls
(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.
Read more1 Nov 2023 16:35
London close: Stocks rise ahead of US Fed policy decision
(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.
Read more1 Nov 2023 08:51
TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy
(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.
Read more1 Nov 2023 08:50
LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles
(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.
Read more1 Nov 2023 07:40
LONDON BRIEFING: GSK raises annual guidance following Arexvy launch
(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.
Read more1 Nov 2023 07:27
GSK hikes guidance after strong third quarter
(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.
Read more30 Oct 2023 09:01
IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial
GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.
Read more30 Oct 2023 07:06
GSK's Jemperli sees success in endometrial cancer trial
(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.
Read more